MCP Server For Financial Data by EODHD Learn more

Volitionrx Ltd icon

Volitionrx Ltd (VNRX AMEX) stock market data APIs

$0.2209 0(0%)
as of October 8, 2026
Try our APIs with free plan!

Volitionrx Ltd Financial Data Overview

Price chart is built with Anychart

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Prev. Close 0.2209
Open 0.2251
High 0.2341
Low 0.2168
52 wk Range 0.2165-10.314
Market Cap 6 595 K
Shares Outstanding 30 061 K
Revenue 2 458 K
EPS -0.78
Beta 1.166

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


ETFs with Volitionrx Ltd (top by weight)

Ticker
100-day Price Change
Weight
IS0R.F iShares High Yield Corporate Bond UCITS
0.43 (0.54%)
0.00
IS0R.XETRA iShares $ High Yield Corp Bond UCITS ETF USD (Dist) EUR
0.04 (0.05%)
0.00

* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get Volitionrx Ltd data using free add-ons & libraries


Get Volitionrx Ltd Fundamental Data

Volitionrx Ltd logo

Volitionrx Ltd Fundamental data includes:

  • Net Revenue: 2 458 K
  • EBITDA: -18 572 584
  • Earnings Per Share: -3
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get Volitionrx Ltd Earnings data

Corporate Events Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2026-08-13
  • EPS/Forecast: -0.68
GET THE PACKAGE

Get Volitionrx Ltd End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE

Volitionrx Ltd News

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space. New

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026,...

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026,...

Volition (VNRX) Q2 2026 Earnings Call Transcript

Volition (VNRX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, Aug. 14, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Group Chief Marketing and Communications Officer - Louise Batchelor Group Chief Executive Officer - Came...

VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts

VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts

With an upside potential of 1451.32%, VolitionRx Limited (NYSEAMERICAN:VNRX) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 15, Cameron Reynolds, President ...

Get Volitionrx Ltd fresh news feed via Financial News API

Corporate Events Calendar & News package for

$19.99/mo.

Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE

Send the request

Leave your email and our team will contact you ASAP.